School of Biomedical Sciences - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/57545

Filters

2010 - 2019 1 2020 - 2022 1
2
Reset filters

Settings
Statistics
Citations
Author: Wilkinson-Berka, Jennifer × Author: Binger, Katrina ×

Search Results

Now showing 1 - 2 of 2
  • Item
    Thumbnail Image
    Tetraspanin CD82 restrains phagocyte migration but supports macrophage activation
    McGowan, ENS ; Wong, O ; Jones, E ; Nguyen, J ; Wee, J ; Demaria, MC ; Deliyanti, D ; Johnson, CJ ; Hickey, MJ ; McConville, MJ ; Wilkinson-Berka, JL ; Wright, MD ; Binger, KJ (CELL PRESS, 2022-07-15)
    Phagocytes migrate into tissues to combat infection and maintain tissue homeostasis. As dysregulated phagocyte migration and function can lead to inflammation or susceptibility to infection, identifying molecules that control these processes is critical. Here, we show that the tetraspanin CD82 restrains the migration of neutrophils and macrophages into tissues. Cd82 -/- phagocytes exhibited excessive migration during in vivo models of peritoneal inflammation, superfusion of CXCL1, retinopathy of prematurity, and infection with the protozoan parasite L. mexicana. However, with the latter, while Cd82 -/- macrophages infiltrated infection sites at higher proportions, cutaneous L. mexicana lesions were larger and persisted, indicating a failure to control infection. Analyses of in vitro bone-marrow-derived macrophages showed CD82 deficiency altered cellular morphology, and impaired gene expression and metabolism in response to anti-inflammatory activation. Altogether, this work reveals an important role for CD82 in restraining phagocyte infiltration and mediating their differentiation in response to stimulatory cues.
  • Item
    Thumbnail Image
    Candesartan Attenuates Diabetic Retinal Vascular Pathology by Restoring Glyoxalase-I Function
    Miller, AG ; Tan, G ; Binger, KJ ; Pickering, RJ ; Thomas, MC ; Nagaraj, RH ; Cooper, ME ; Wilkinson-Berka, JL (AMER DIABETES ASSOC, 2010-12)
    OBJECTIVE: Advanced glycation end products (AGEs) and the renin-angiotensin system (RAS) are both implicated in the development of diabetic retinopathy. How these pathways interact to promote retinal vasculopathy is not fully understood. Glyoxalase-I (GLO-I) is an enzyme critical for the detoxification of AGEs and retinal vascular cell survival. We hypothesized that, in retina, angiotensin II (Ang II) downregulates GLO-I, which leads to an increase in methylglyoxal-AGE formation. The angiotensin type 1 receptor blocker, candesartan, rectifies this imbalance and protects against retinal vasculopathy. RESEARCH DESIGN AND METHODS: Cultured bovine retinal endothelial cells (BREC) and bovine retinal pericytes (BRP) were incubated with Ang II (100 nmol/l) or Ang II+candesartan (1 μmol/l). Transgenic Ren-2 rats that overexpress the RAS were randomized to be nondiabetic, diabetic, or diabetic+candesartan (5 mg/kg/day) and studied over 20 weeks. Comparisons were made with diabetic Sprague-Dawley rats. RESULTS: In BREC and BRP, Ang II induced apoptosis and reduced GLO-I activity and mRNA, with a concomitant increase in nitric oxide (NO(•)), the latter being a known negative regulator of GLO-I in BRP. In BREC and BRP, candesartan restored GLO-I and reduced NO(•). Similar events occurred in vivo, with the elevated RAS of the diabetic Ren-2 rat, but not the diabetic Sprague-Dawley rat, reducing retinal GLO-I. In diabetic Ren-2 rats, candesartan reduced retinal acellular capillaries, inflammation, and inducible nitric oxide synthase and NO(•), and restored GLO-I. CONCLUSIONS: We have identified a novel mechanism by which candesartan improves diabetic retinopathy through the restoration of GLO-I.